[
  {
    "sentence": "TMEM97 has the highest expression in luminal B tumors (Fig. 1A).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In an analogous manner, PGRMC1 was expressed at higher levels in ER− tumors, PR− tumors, and ER−/HER2− tumors (Fig. 1B).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "PGRMC1 was also expressed at higher levels in tumors of higher grade (P = 2.5 × 10−14) and smaller size (P = 4.7 × 10−7; Fig. 1C).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel C",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In the integrated dataset, LDLR and TMEM97 also had the highest expression in ER− disease (P = 4.7e−14 and P = 0.041, respectively; Fig. 1B); LDLR and TMEM97 were also each expressed at higher levels in tumors of higher grade (P = 1.1 × 10−08 and 6.1 × 10−64, respectively; Fig. 1C).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel C",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The results demonstrated that PGRMC1 expression is associated with a higher risk of early relapse (within 5 years) across all patients with breast cancer [HR = 1.25; 95% confidence interval (CI) = 1.12–1.39; P = 6.4 × 10−5; Fig. 2A].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Within the basal subtype, PGRMC1 expression was also associated with relapse (HR = 1.29; 95% CI = 1.04–1.60; P = 0.018; Fig. 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The risk of early recurrence with TMEM97 was present only in ER+/HER2− disease (HR = 1.5; 95% CI = 1.35–1.67; P = 5.4−14) and ER+ malignancies (HR = 1.49; 95% CI = 1.31–1.68; P = 3.1−10) and was not present in ER−/HER2− (HR = 1.05; 95% CI = 0.88–1.25; P = 0.63) or ER− disease (HR = 1.02; 95% CI = 0.89–1.17; P = 0.75; Fig. 3A and B).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The CIs for PAM50, Oncotype DX, and our new proliferation signature were from 0.63 to 0.66, which is moderate and reasonable, consistent with these prior reported data (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The CIs for PAM50, Oncotype DX, and our new proliferation signature were from 0.63 to 0.66, which is moderate and reasonable, consistent with these prior reported data (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "This is when the sigma-2–PGRMC1–LDL complex becomes crucial, as it can enhance the rate of internalization by up to tenfold (Fig. 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "This is when the sigma-2–PGRMC1–LDL complex becomes crucial, as it can enhance the rate of internalization by up to tenfold (Fig. 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  }
]